Compare Allstate Corp (ALL) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs Cronos Group Inc — how do they compare? Allstate Corp trades at $262.54 (market cap $68.19B), while Cronos Group Inc trades at $3.08 (market cap $1.11B). The key difference: Allstate Corp is far larger — about 61.4× Cronos Group Inc's market cap, and Allstate Corp pays a 1.6% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| ALL | CRON | |
|---|---|---|
Market Cap | $68.19B | $1.11B |
Sector | Financials | Health |
52-Week High | $275.11 | $3.27 |
52-Week Low | $190.00 | $2.30 |
Enterprise Value | $76.84B | $310.67M |
Dividend Yield | 1.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $267.00, down 2.95% on the day, but maintains a bullish technical signal with strong fundamental momentum. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, and has consistently exceeded expectations in recent quarters. Revenue growth is steady, with 2025 revenue at $67.07 billion and net income margin improving to 19.19%. The stock is attractively valued with a P/E of 5.35 and offers a dividend, with recent payouts of $1.08 per share.
The outlook for ALL is positive, driven by strong underwriting performance and earnings beats, though sustainability of peak profitability is a concern. Investment opportunity lies in its low valuation and dividend yield, but risks include potential normalization of underwriting results and competitive pressures. Analyst consensus is mixed with a $266.54 price target, indicating limited near-term upside from current levels.
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
